Heterozygote Advantage of the Type II Deiodinase Thr92Ala Polymorphism on Intrahospital Mortality of COVID-19.

Autor:	de Lima Beltrão FE; Lauro Wanderley University Hospital, Federal University of Paraíba, João Pessoa, Paraíba, Brazil.; Post-Graduation Program in Nutritional Sciences, Department of Nutrition, Center for Health Sciences, Federal University of Paraíba, João Pessoa, Paraíba, Brazil.; University Center of João Pessoa - UNIPE, João Pessoa, PB, Brazil., de Almeida Beltrão DC; University Center of João Pessoa - UNIPE, João Pessoa, PB, Brazil., Carvalhal G; Center for Biological and Health Sciences, Federal University of Campina Grande, Campina Grande, Paraíba, Brazil., de Lima Beltrão FE; Lauro Wanderley University Hospital, Federal University of Paraíba, João Pessoa, Paraíba, Brazil., de Souza Braga Filho J; Bioregulation Department, Health and Science Institut, Federal University of Bahia, Salvador, Bahia, Brazil., de Brito Oliveira J; Bioregulation Department, Health and Science Institut, Federal University of Bahia, Salvador, Bahia, Brazil., de Jesus JDS; Bioregulation Department, Health and Science Institut, Federal University of Bahia, Salvador, Bahia, Brazil., Machado GJR; Bioregulation Department, Health and Science Institut, Federal University of Bahia, Salvador, Bahia, Brazil., Dos Santos Silva H; Bioregulation Department, Health and Science Institut, Federal University of Bahia, Salvador, Bahia, Brazil., Teixeira HMP; Bioregulation Department, Health and Science Institut, Federal University of Bahia, Salvador, Bahia, Brazil., Rodrigues JL; Laboratory of Immunopharmacology and Molecular Biology, Health Sciences Institute, Federal University of Bahia, Brazil., de Figueiredo CAV; Laboratory of Immunopharmacology and Molecular Biology, Health Sciences Institute, Federal University of Bahia, Brazil., Dos Santos Costa R; Laboratory of Immunopharmacology and Molecular Biology, Health Sciences Institute, Federal University of Bahia, Brazil., Hecht F; The Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Bianco AC; Section of Endocrinology and Metabolism, Division of the Biological Sciences, University of Chicago, Chicago, IL,USA., da Conceição Rodrigues Gonçalves M; Post-Graduation Program in Nutritional Sciences, Department of Nutrition, Center for Health Sciences, Federal University of Paraíba, João Pessoa, Paraíba, Brazil., Ramos HE; Bioregulation Department, Health and Science Institut, Federal University of Bahia, Salvador, Bahia, Brazil.; Postgraduate Program in Medicine and Health, Medical School of Medicine, Federal University of Bahia, Salvador, Brazil.; Postgraduate Program in Interactive Processes of Organs and Systems, Health & Science Institute, Federal University of Bahia, Salvador, BA, Brazil.
Jazyk:	angličtina
Zdroj:	The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2022 May 17; Vol. 107 (6), pp. e2488-e2501.
DOI:	10.1210/clinem/dgac075
Abstrakt:	Context: The type 2 deiodinase and its Thr92Ala-DIO2 polymorphism have been linked to clinical outcomes in acute lung injury and pulmonary fibrosis. Objective: Our objectives were to evaluate were cumulative mortality during admission according to Thr92Ala-DIO2 polymorphism. Methods: Here we conducted an observational, longitudinal, and prospective cohort study to investigate a possible association between the Thr92Ala-DIO2 polymorphism and intrahospital mortality from COVID-19 in adult patients admitted between June and August 2020. Blood biochemistry, thyroid function tests, length of stay, comorbidities, complications, and severity scores were also studied according to Thr92Ala-DIO2 polymorphism. Results: In total, 220 consecutive patients (median age 62; 48-74 years) were stratified into 3 subgroups: Thr/Thr (n = 79), Thr/Ala (n = 119), and Ala/Ala (n = 23). While the overall mortality was 17.3%, the lethality was lower in Ala/Thr patients (12.6%) than in Thr/Thr patients (21.7%) or Ala/Ala patients (23%). The heterozygous genotype (Thr/Ala) was associated with a 47% reduced risk of intrahospital mortality whereas univariate and multivariate logistic regression adjusted for multiple covariates revealed a reduction that ranged from 51% to 66%. The association of the Thr/Ala genotype with better clinical outcomes was confirmed in a metanalysis of 5 studies, including the present one. Conclusion: Here we provide evidence for a protective role played by Thr92Ala-DIO2 heterozygosity in patients with COVID-19. This protective effect follows an inheritance model known as overdominance, in which the phenotype of the heterozygote lies outside the phenotypical range of both homozygous. (© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu